Risk assessment and prophylaxis of venous thromboembolism in non-surgical patients: cancer as a risk factor.
It is well documented that cancer patients undergoing surgery are at a sufficiently high risk of developing venous thromboembolism (VTE) to justify the routine use of prophylactic anticoagulant therapy. However, despite many studies showing an increased incidence of VTE associated with the use of chemotherapy in patients with breast carcinoma and with the use of indwelling venous access catheters in patients with various kinds of cancer, thromboprophylactic strategies are not yet widely used.
Department of Internal Medicine, Academic Medical Centre, Amsterdam, The Netherlands. j.m.otten@amc.uva.nl
H M
HM
Otten
M H
MH
Prins
S M
SM
Smorenburg
B A
BA
Hutten
D000970:Antineoplastic Agents / Q000009:adverse effects; D018931:Antineoplastic Agents, Hormonal / Q000009:adverse effects; D001932:Brain Neoplasms / Q000150:complications / Q000188:drug therapy / Q000601:surgery; D001943:Breast Neoplasms / Q000150:complications / Q000188:drug therapy; D002405:Catheterization, Central Venous / Q000009:adverse effects; D003131:Combined Modality Therapy; D005260:Female; D005910:Glioma / Q000150:complications / Q000188:drug therapy / Q000601:surgery; D006801:Humans; D015994:Incidence; D008223:Lymphoma / Q000150:complications / Q000188:drug therapy; D008297:Male; D009369:Neoplasms / Q000097:blood / Q000453:epidemiology* / Q000628:therapy; D011446:Prospective Studies; D018570:Risk Assessment; D019851:Thrombophilia / Q000209:etiology*; D020246:Venous Thrombosis / Q000453:epidemiology / Q000209:etiology / Q000517:prevention & control*
D000970:Antineoplastic Agents; D018931:Antineoplastic Agents, Hormonal